ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[Veratric acid relieves oxidative stress and DSS-induced colitis in mice by activating the Nrf2/HO-1 signaling pathway].
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the molecular mechanism by which veratric acid (VA) ameliorates oxidative stress injury and intestinal barrier dysfunction in mice with dextran sulfate sodium (DSS)-induced colitis.
methodsThirty male C57BL/6 mice were randomized equally into control group, DSS model group, and VA treatment group. The mice were assessed for changes in body weight, disease activity index (DAI), colon length, and colonic histopathology. Colonic expressions of TNF-α, IL-6, and IL-10 and oxidative stress markers (SOD, GSH, MDA, and COX-2) were determined using ELISA, and the expressions of tight junction proteins (ZO-1 and claudin-1) and Nrf2/HO-1 pathway proteins were detected using immunofluorescence staining and Western blotting. In Caco-2 cells with H₂O₂-induced oxidative stress, ROS accumulation was examined using flow cytometry and a DCFH-DA probe, and Nrf2 inhibitor (ML385) was used to validate the mechanism of VA for ameliorating oxidative stress.
resultsVA treatment significantly alleviated DSS-induced body weight loss, colon shortening and the increase of DAI score of the mice, resulting also in improved crypt structure and increased expressions of ZO-1 and claudin-1 and the number of goblet cells. VA obviously reduced colonic levels of TNF‑α and IL-6, increased the level of IL-10, and reversed DSS-induced decreases in SOD and GSH activity and increases in MDA and COX-2 levels. In H₂O₂-treated Caco-2 cells, VA decreased ROS-positive cell rate and intracellular ROS accumulation, and increased cellular expressions of claudin-1 and ZO-1. Mechanistically, VA promoted the expressions of Nrf2 and the downstream HO-1 protein, and ML385 partially reversed ROS-reducing effect of VA.
conclusionsVA enhances antioxidant defense, inhibits inflammation, and repairs intestinal barrier function in mice with DSS-induced colitis by activating the Nrf2/HO-1 pathway, suggesting a novel strategy for treatment of inflammatory bowel disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.